Graybug Vision, Inc.

Mireca Medicines Gmbh

Per Ekström

Hans-Gottfried Genieser

Andreas Rentsch

Valeria Marigo

Frank Schwede

Pieter Jaap Gaillard

Dragana Trifunovic

Ayse Sahaboglu Tekgoz

Francois Paquet-Durand

François Paquet-Durand

Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3', 5&#x2032;-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.

Equatorially modified polymer linked multimers of guanosine-3', 5&#x2032;-cyclic monophosphates

The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3', 5&#x2032;-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.

Targeted liposomal delivery of cGMP analogues

Growing community of inventors

Lund, Sweden

Per Ekström